Device Trial Radar · NCT05898230
Retrospective Clinical Data Collection on Carbomedics OptiForm Mitral Heart Valve
Last checked: Nov 20, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Nov 23, 2023
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Corcym S.r.lNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 12, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the medium- to long-term safety of the Carbomedics OptiForm Mitral Heart Valve after the implantation for mitral valve disease in the Chinese population. The study is designed as a post-market, retrospective, single arm and multicentric data collection
Conditions
- Mitral Valve Disease
Interventions
Mitral Valve ReplacementDevice
Mitral Valve Replacement with Carbomedics OptiForm Mitral Heart Valve
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prosthetic Valve DysfunctionTime frame: up to 7-8 year
- MortalityTime frame: up to 7-8 year
- Valve-related bleedingTime frame: up to 7-8 year
4 more outcomes with a free account
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The second Xiangya Hospital of Central South University
Changsha, China · Recruiting
West China hospital of Sichuan University
Chendu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.